- GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNAc-siRNA format with potential for best-in-class potency and durability
- GSK collaboration continues to span all Wave modalities, including RNA editing, with target validation ongoing in multiple therapy areas
- Wave is on track to initiate a clinical trial of its wholly owned INHBE program for obesity in 1Q 2025, which also uses the company's next generation siRNA
As Part Of Wave Life Sciences' Ongoing Collaboration With GSK, GSK Has Selected Its First Two Oligonucleotide Programs, GSK Will Provide An Initiation Payment Of $12M
Company Profile